# EDGAR Filing Document

**Accession Number:** 0000012208
**File Stem:** 0000012208-23-000009
**Filing Date:** 2023-1
**Character Count:** 7311
**Document Hash:** 009e943e076f961a00207ddf554c7a88
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000012208-23-000009.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0000012208-23-000009

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 40

**CONFORMED PERIOD OF REPORT**: 20230110

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-RAD LABORATORIES, INC.
- **CENTRAL INDEX KEY:** 0000012208
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 941381833
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-07928
- **FILM NUMBER:** 23521496

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 ALFRED NOBEL DRIVE
- **CITY:** HERCULES
- **STATE:** CA
- **ZIP:** 94547
- **BUSINESS PHONE:** 5107247000

**MAIL ADDRESS:**
- **STREET 1:** 1000 ALFRED NOBEL DRIVE
- **CITY:** HERCULES
- **STATE:** CA
- **ZIP:** 94547

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIO RAD LABORATORIES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version="1.0" ? bio-20230110

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report: January 10, 2023** 

**(Date of earliest event reported)**

**BIO-RAD LABORATORIES, INC.** 

**(Exact name of registrant as specified in its charter)**

**Commission File Number: 1-7928** 

---

| | |
|:---|:---|
| **Delaware** | **94-1381833** |
| **(State or other jurisdiction of incorporation)** | **(I.R.S. Employer Identification No.)** |

---

**1000 Alfred Nobel Dr.**

**Hercules, California 94547** 

**(Address of principal executive offices, including zip code)**

**(510)724-7000** 

**(Registrant's telephone number, including area code)**

---

| | |
|:---|:---|
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act:  | Securities registered pursuant to Section 12(b) of the Act:  | Securities registered pursuant to Section 12(b) of the Act:  |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Class A Common Stock, Par Value $0.0001 per share | BIO | New York Stock Exchange |
| Class B Common Stock, Par Value $0.0001 per share | BIOb | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as deﬁned in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

---

| | | |
|:---|:---|:---|
| | Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

------

**ITEM 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

As previously announced, Norman Schwartz, President and CEO of Bio-Rad Laboratories, Inc. ("Bio-Rad"), plans to present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:30 p.m. Pacific Time. The presentation will be followed by a Q&A session with participation from Bio-Rad's Executive Vice President and COO Andrew Last, and Executive Vice President and CFO Ilan Daskal. A link to a live webcast of the event will be accessible in the Investor Relations section of Bio-Rad's website at bio-rad.com. A copy of the J.P. Morgan Healthcare Conference presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**ITEM 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit</u>

 <u>No</u>. &nbsp;&nbsp;&nbsp;&nbsp; <u>Description</u>

99.1 <u>[J.P. Morgan Healthcare Conference](biojpm2023pdffinalv2.htm)[Presentation of Bio-Rad Laboratories, Inc. dated January 10,](biojpm2023pdffinalv2.htm)[2023](biojpm2023pdffinalv2.htm)</u>

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **BIO-RAD LABORATORIES, INC.** | **BIO-RAD LABORATORIES, INC.** |
| Date: | January 10, 2023 | By: | /s/ Ilan Daskal |
|  |  |  | Ilan Daskal |
|  |  |  | Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

![](biojpm2023pdffinalv2001.jpg)

------

![](biojpm2023pdffinalv2002.jpg)

------

![](biojpm2023pdffinalv2003.jpg)

------

![](biojpm2023pdffinalv2004.jpg)

------

![](biojpm2023pdffinalv2005.jpg)

------

![](biojpm2023pdffinalv2006.jpg)

------

![](biojpm2023pdffinalv2007.jpg)

------

![](biojpm2023pdffinalv2008.jpg)

------

![](biojpm2023pdffinalv2009.jpg)

------

![](biojpm2023pdffinalv2010.jpg)

------

![](biojpm2023pdffinalv2011.jpg)

------

![](biojpm2023pdffinalv2012.jpg)

------

![](biojpm2023pdffinalv2013.jpg)

------

![](biojpm2023pdffinalv2014.jpg)

------

![](biojpm2023pdffinalv2015.jpg)

------

![](biojpm2023pdffinalv2016.jpg)

------

![](biojpm2023pdffinalv2017.jpg)

------

![](biojpm2023pdffinalv2018.jpg)

------

![](biojpm2023pdffinalv2019.jpg)

------

![](biojpm2023pdffinalv2020.jpg)

------

![](biojpm2023pdffinalv2021.jpg)

------

![](biojpm2023pdffinalv2022.jpg)

------

![](biojpm2023pdffinalv2023.jpg)

------

![](biojpm2023pdffinalv2024.jpg)

------

![](biojpm2023pdffinalv2025.jpg)

------

![](biojpm2023pdffinalv2026.jpg)

------